Sirolimus for Injection (Albumin-bound)
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Sirolimus for Injection (Albumin-bound) is one of 29 small molecule programs targeting Epithelioid Hemangioendothelioma. It is currently in Phase 3.
2
Indications
7
Total Trials
4
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Sirolimus for Injection (Albumin-bound)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ibrance
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Breast Cancer2 trials
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Active, not recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolledPEComa1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details